Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Two Parts Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of BAR502 in Healthy Subjects

NCT06705998 is registered in ClinicalTrials.gov with BAR Pharmaceuticals s.r.l. as lead sponsor.

NCT NCT06705998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06705998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Two Parts Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of BAR502 in Healthy Subjects
Lead sponsor
BAR Pharmaceuticals s.r.l.
Phase
Phase 1
Overall status
Completed
Start date
December 4, 2024
Completion date
June 3, 2026
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nash